Based on strictly defined criteria, 48 patients were judged to have Crohn's disease in a retrospective 10 year survey of Dunedin Hospital case notes. An apparent increase in the frequency of this disease in the Otago area is documented. Age (mean 39.5 years) and sex distribution (female/male:1.6/1) of cases and the patterns of clinical presentation are in accordance with similar studies in other countries. Mean follow up was for 28 months (range 3-108 months). The dominant localisation of the disease was to the large bowel only (60%), or large bowel plus terminal ileum (17%) with only 23% having disease confined to the small bowel. This is the reverse of experience in a similar survey recently reported from Auckland. No cases were detected in Polynesians in either survey. The difficulty of early and accurate diagnosis of Crohn's disease is emphasised. Although 21 (44%) of the patients required some surgery, no deaths were recorded in these patients.

Download full-text PDF

Source

Publication Analysis

Top Keywords

crohn's disease
12
large bowel
8
disease
5
disease ten
4
ten year
4
year retrospective
4
retrospective review
4
review dunedin
4
dunedin hospitals
4
hospitals based
4

Similar Publications

Background: Colonic stenosis in Crohn's disease (CD) is uncommon, and data on surgery-free survival are limited. This study aimed to determine surgery-free survival rates and identify associated factors.

Patients And Methods: A retrospective study was conducted from 2003 to 2022, including patients with CD complicated by colonic stenosis.

View Article and Find Full Text PDF

Background: Fecal microbiota, live-jslm (RBL; REBYOTA®), is the first single-dose, broad consortia, microbiota-based live biotherapeutic approved by the US Food and Drug Administration to prevent recurrent Clostridioides difficile infection (rCDI) in adults following standard-of-care antimicrobials. Inflammatory bowel disease (IBD) is a common risk factor for rCDI, yet patients with IBD are often excluded from prospective trials. This subgroup analysis of PUNCH CD3-OLS (NCT03931941) evaluated the safety and efficacy of RBL in participants with rCDI and IBD.

View Article and Find Full Text PDF

Background/objectives: Janus kinase inhibitors open new horizons for small-molecule drugs in treating inflammatory bowel disease, with ritlecitinib demonstrating significant efficacy in clinical trials for ulcerative colitis and Crohn's disease. Ritlecitinib, a second-generation JAK3 inhibitor, is a novel therapeutic agent for alopecia areata and other autoimmune conditions.

Methods: A new stability-indicating UHPLC-DAD-MS/MS method was developed, validated, and applied for a forced degradation study of ritlecitinib under ICH guidelines.

View Article and Find Full Text PDF

The introduction of anti-tumor necrosis factor-α (anti-TNF-α) agents, particularly infliximab (IFX) and adalimumab (ADA), has significantly expanded the therapeutic arsenal for inflammatory bowel disease (IBD). While these biologics have demonstrated substantial efficacy, they are associated with a spectrum of potential adverse events (AEs). This study aims to evaluate and document these AEs to facilitate optimal patient selection and monitoring strategies of patients undergoing these therapies.

View Article and Find Full Text PDF

Inflammatory bowel diseases (IBD) including Crohn's disease (CD) and ulcerative colitis (UC) are chronic, relapsing conditions characterized by dysregulated immune responses and persistent intestinal inflammation. This review aims to examine new potential therapeutic targets in IBD starting from the STRIDE-II statements. Key targets now include clinical remission, endoscopic remission, and biomarker normalization (such as C-reactive protein and fecal calprotectin).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!